Canada Lung Cancer Therapeutics Market Size, Share, Price, Trends, Growth, Analysis, Outlook, Report, Forecast 2023-2028

Report Overview

Canadas Lung Cancer Therapeutics market size stood at around USD XX billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of X.X% during the forecast period.

Canadas lung cancer therapeutics market is expected to grow significantly over the forecast period. In Canada, Lung cancer is the leading cause of cancer deaths for both males (25.2% of cancer deaths) and females (26.1% of cancer deaths). In Canada, lung cancer accounts for 13% of all new cancer cases & 25% of deaths due to cancer. and It is estimated that nearly 29,300 Canadians will develop lung cancer in 2019 and 21,000 will die from it. The incidence of lung cancer remains higher in males (66.0 per 100,000) than females (59.6 per 100,000). Smoking is thought of as the main cause of lung cancer, though lung cancer also follows in non-smokers.

Market Driving Factors

The driving factors for the growth of the Lung Cancer Therapeutics market in Canada include rising prevalence, increasing patient alertness, persistent investment in R&D, and greater adoption of sophisticated and advanced therapies. Growth in the lung cancer therapeutics market can also be attributed to patients constant contact with radiation and carcinogens. Furthermore, the late advent of disease symptoms leads to postponement in diagnosis and progression in the cancer stage, which results in the rising cost of the treatment. Increasing adoption and demand for targeted therapies, which is considered to be the foundation of precision medicine is one of the most prominent driving factors for the growth of Canadas Lung Cancer Therapeutics Market.

Get PDF Sample Report Now! @ https://www.prudentmarkets.com/sample-request/139720/

Major Players

In Canada Majority of the lung cancer therapeutics are being manufactured by global key players. Recently Takeda Canada Inc. has announced that Health Canada has issued approval for ALUNBRIG® (brigatinib tablets) as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase positive (ALK+) locally advanced or metastatic non-small cell lung cancer (NSCLC).

Roche Canada has also announced that its medicine Tecentriq® (atezolizumab) got Health Canada approval to use in combination with carboplatin & etoposide for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC), representing the first new treatment for the disease in more than two decades. Tecentriq is the first and only approved cancer immunotherapy agent in Canada for first-line SCLC.

Other Major Players are Boehringer Ingelheim, Astra Zenca, Pfizer, Eli Lilly and Company.

The Canada Lung Cancer Therapeutics Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global Canada Lung Cancer Therapeutics market. This report explores all the key factors affecting the growth of the global Canada Lung Cancer Therapeutics market, including demand-supply scenario, pricing structure, profit margins, production, and value chain analysis.

To Know More About COVID-19 Impact On Canada Lung Cancer Therapeutics Market @ https://www.prudentmarkets.com/sample-request/139720/

Market Segmentation

By Treatment Type:

Canada's Lung cancer therapeutics market can be segmented based on treatment type as Chemotherapy, Radiotherapy, surgery, and Other Drugs. The chemotherapy and minimally invasive surgeries segment which is a subtype of surgeries is expected to grow at the highest CAGR during the forecast period. Fewer incisions, fewer hospital stays, and faster recovery are the major factors that are expected to fuel the growth of the minimally invasive surgeries segment.

By Cancer Type:

Based on the cancer type, the market is segmented into the Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC), where NSCLC leads 85% of the total share. The words small and non-small reference the size of the cells found in the tumor and not the size of the tumor itself.

By Distribution Channel:

Canada's lung cancer market can be segmented based on its distribution channel into Hospital Pharmacies, Clinics, Ambulatory Surgical Centres, Retail Pharmacies, and Online pharmacies. The hospitals & clinics segment is forecasted to control a massive share in the end-user segment through the forecast period.

Major Players

In Canada Majority of the lung cancer therapeutics are being manufactured by global key players. Recently Takeda Canada Inc. has announced that Health Canada has issued approval for ALUNBRIG® (brigatinib tablets) as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase positive (ALK+) locally advanced or metastatic non-small cell lung cancer (NSCLC).

Roche Canada has also announced that its medicine Tecentriq® (atezolizumab) got Health Canada approval to use in combination with carboplatin & etoposide for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC), representing the first new treatment for the disease in more than two decades. Tecentriq is the first and only approved cancer immunotherapy agent in Canada for first-line SCLC.

Other Major Players are Boehringer Ingelheim, Astra Zenca, Pfizer, Eli Lilly and Company.

Prudent Markets provides attractive discounts that fit your needs. Customization of the reports as per your requirement is also offered. Get in touch with our sales team, who will guarantee you a report that suits your needs.

Speak To Our Analyst For A Discussion On The Above Findings, And Ask For A Discount On The Report @ https://www.prudentmarkets.com/discount-request/139720/

The report covers the competitive analysis of the market. As the demand is driven by a buyer's paying capacity and the rate of item development, the report shows the important regions that will direct growth. This section exclusively shares insight into the budget reports of big-league members of the market helping key players and new entrants understand the potential of investments in the Global Canada Lung Cancer Therapeutics Market. It can be better employed by both traditional and new players in the industry for complete know-how of the market.

Strategic Points Covered in Table of Content of Global Canada Lung Cancer Therapeutics Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Canada Lung Cancer Therapeutics market
Chapter 2: Exclusive Summary - the basic information of the Canada Lung Cancer Therapeutics Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the Canada Lung Cancer Therapeutics
Chapter 4: Presenting the Canada Lung Cancer Therapeutics Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User and Region/Country
Chapter 6: Evaluating the leading manufacturers of the Canada Lung Cancer Therapeutics market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile
Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions
Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Any Questions? Feel Free To Enquire Here. We Will put you on the Right Path @ https://www.prudentmarkets.com/enquiry-request/139720/

Free Customization on the basis of client requirements on Immediate purchase:
1- Free country-level breakdown of any 5 countries of your interest.
2- Competitive breakdown of segment revenue by market players.

Customization of the Report:
This report can be customized to meet the client's requirements. Please connect with our sales team (sales@prudentmarkets.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +91 83560 50278 || USA/Canada(Toll Free): 1800-601-6071 to share your research requirements.

Get ready to Recognize the pros and cons of the regulatory framework, local reforms, and its effect on the Industry. Understand how the Leaders in Intelligent Network are keeping themselves one stage forward with our most up-to-date survey analysis.

In conclusion, the Canada Lung Cancer Therapeutics Market report is a genuine source for accessing the research data which is projected to exponentially grow your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis and PESTLE analysis is also incorporated in the report.

Contact Us:
Allan Carter
Andheri, Maharashtra, 400102
USA/Canada(Toll Free): 1800-601-6071
Direct Line: +91 83560 50278
Mail: sales@prudentmarkets.com
Web: www.prudentmarkets.com

About Us:
We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client's disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy.

This release was published on openPR.